What is the growth rate and management plan for vestibular (acoustic neuroma) schwannomas?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The percentage of coincidental vestibular schwannoma that enlarge on follow-up is approximately 7.2% after a stable period of 5 years following diagnosis, as reported in a large prospectively followed cohort of extra- and intracanalicular tumors 1.

Key Points to Consider

  • The growth rate of vestibular schwannomas is typically slow, at 1-2 mm per year, though this varies considerably with some tumors showing no growth while others grow more rapidly.
  • For small tumors (<2 cm) without significant symptoms, observation with regular MRI monitoring every 6-12 months is often recommended initially.
  • Treatment options for growing tumors or those causing progressive symptoms include microsurgery, stereotactic radiosurgery (such as Gamma Knife), or fractionated radiotherapy.
  • The choice between observation and intervention should be individualized based on tumor size, location, growth rate, patient age, hearing status, and other symptoms.
  • Regular follow-up is essential regardless of the management approach chosen, with annual MRI follow-up recommended for 5 years in patients with untreated tumors, and follow-up intervals can be prolonged thereafter if the tumor remains stable 1.

Management Approach

  • Stereotactic radiosurgery (SRS) is a noninvasive treatment with at least equivalent rates of tumor control and hearing preservation as compared to microsurgical resection, with better facial nerve preservation 1.
  • Upfront SRS is an effective treatment in achieving tumor control with similar rates of hearing preservation as compared to conservative surveillance (CS) 1.
  • CS should be considered as the recommended approach for older patients and no appreciable tumor growth regardless of hearing status 1.

Important Considerations

  • Patients should understand that even with treatment, hearing preservation is not guaranteed, and potential complications include facial nerve dysfunction, balance problems, and headaches.
  • The management of vestibular schwannomas requires a multidisciplinary approach, taking into account the patient's individual characteristics, tumor size, and growth rate.

From the Research

Growth Rate of Vestibular Schwannomas

  • The growth rate of vestibular schwannomas can vary, and there is no consensus on the exact percentage of coincidental vestibular schwannomas that enlarge on follow-up 2.
  • However, it is recommended to obtain MRIs annually for 5 years, with interval lengthening thereafter with tumor stability 2.
  • Cystic vestibular schwannomas may behave differently than their solid counterparts, with a higher risk of rapid growth and lower rates of complete resection 2.

Management Plan for Vestibular Schwannomas

  • The management plan for vestibular schwannomas depends on various factors, including tumor size, location, symptoms, and patient preferences 3, 4.
  • Treatment options include observation with serial imaging, stereotactic radiation, and microsurgical removal 3, 5.
  • Surgical approaches, such as translabyrinthine, retrosigmoid, and middle fossa, have their advantages and disadvantages, and the goal of surgery is complete eradication of tumor with preservation of hearing and facial nerve function when possible 5.
  • Exclusive surgical treatment for vestibular schwannoma residuals has a very low failure rate in terms of requiring further treatment, and the choice of surgical approach does not influence facial nerve function 6.

Follow-up and Imaging

  • Postoperative evaluation should be performed with postcontrast 3-D T1 MPRAGE, with nodular enhancement considered suspicious for recurrence 2.
  • Imaging follow-up should be adjusted accordingly for continued surveillance if any change in nodular enhancement is demonstrated 2.
  • For patients receiving gross total resection, a postoperative MRI may be considered to document the surgical impression and may occur as late as 1 year after surgery 2.
  • For patients not receiving gross total resection, more frequent surveillance scans are suggested, with annual MRI scans may be reasonable for 5 years 2.

Related Questions

What are the management and treatment options for Vestibular Schwannoma (Acoustic Neuroma)?
What is the management approach for vestibular (acoustic neuroma) schwannomas after initial diagnosis?
What is the management plan for a 30-year-old female patient with bilateral vestibular schwannoma (acoustic neuroma), with the right-sided tumor measuring 3.7cm and compressing the brainstem, causing mass effect and right facial palsy, and the left-sided tumor measuring 2.5cm, given significant growth from previous magnetic resonance imaging (MRI) scans?
Is bilateral conventional radiotherapy with 50.4 Gy (Gray) in 28 fractions a suitable treatment option for simultaneously addressing both vestibular schwannomas?
Is surgical resection of a vestibular schwannoma (benign tumor of the cranial nerves) medically necessary for a 57-year-old patient with a symptomatic 1.4 cm tumor and profound sensorineural hearing loss (SNHL)?
What is the management plan for a patient on Eliquis (apixaban), Brilinta (ticagrelor), and aspirin for conditions like atrial fibrillation or acute coronary syndrome?
What is the recommended treatment for chronic venous insufficiency?
What is the management approach for vestibular (acoustic neuroma) schwannomas after initial diagnosis?
Is additional prophylactic anticoagulation with low molecular weight heparin (LMWH) necessary for a patient already on Rivaroxaban (direct oral anticoagulant (DOAC))?
What are the recommended medical evaluations and treatments for individuals exposed to Agent Orange?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.